Proteome Sciences Providing Biomarker Services to Eisai | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Proteome Sciences today announced a contract with Japanese drug firm Eisai to provide biomarker services for Alzheimer's disease.

Under the terms of the deal, Proteome Sciences, based in Surrey, UK, will measure candidate biomarkers for AD using its AD-TMT-SRM assay set on human samples, it said in a statement.

Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.